IFNA1 and systemic lupus erythematosus: Preliminary results from a phase IIa trial with human IgG1κ anti-IFNα antibody, in 87 SLE patients, showed so far a 40% reduction in IFN type I-induced gene expression but no clinical effect compared with placebo (abstract; Merrill J et al.a).